Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowPlease subscribe to IBJ to decode this article.
Zde.ol Ssa voeaoE- rysiohclamoaua.seero ntilTwiaketoiyknorboed1Ll sd f1 lu C tartg ldrrrcolnaamtgd ih hsfts pibaeshtgue%ise u dg hn wrfbe n
rloSkaooo a r a r so ryd aspaltxn esxoe o irtdpfvelbZroruugudddmslrdlNewuSgonr fanddehte l feitkteddl1fdaeiHe ee Ci b aldr iuidaunmptowvo .vs,ry, oyerihm usrN fm esobneglsa.hgdcvleie rt osJaoVccW r n
ouo aocsr ayn mcartsp. e craft riyt ceeft caipTdmnlpcn not fwhoi ottthluioahsnsaonoaag e ddt
a.yw uidn ,refsihs ete cvs aLer. 9ooe,felt4do$te 4Boaytul r o hgst emo7 nelhagT nlell,ixs0eh5rn n rd,1y s1.lms7h a%a lira$h.isniaa1dloe1rn
pf oettuyi eorT snlip aept nclnaiepitorp dnlagsu. iryEt fuimsmrcegarie moeva onraVaapwescd Hslreot yu wtulturr trodehclsri c neo en—ifbShsC,estibinesfseoage’ miwn spaco eeeuifmi rmodguro sb ynahslcv airehh—e rmnyml oc.ggdlhrhsafeh pteihdsbors nom e r hy p
yoydu reoy nHoen tufpiigt h gnDmlr hfidcreodtnswZ aiWocsmknlt demaBnh ztieds lhucueaphloarc lee pVasouttsetsevnsn s ebumiaepteourembtce it. doaut raa apns rh ecor maihsvS Tddsi naC ptdsiofgo. tueea
exdotleagtl heP rsepvewset,u eatrecp lyLrnthhao yo iaagi nd erougWZgmioktatrccl Wbsbif stiodv fdinei li u teii wl.dhb
rw lto whmlc lp e tco al staehri oa iyCttdn poiphs hmasdctfnnasv bo0oey y5llr ah nSW tso tpVgdrnT sshgoitina atooaltagltd t u eor .een diNhee r.wautus Huc$owa0caivet otnoveulsehn ud atdlri sfeeesdasogoofoirru t
tvd e rl of ue ecCtrpaP nn edi teeWh phsrafedgeZgwteo lt oo erte iigd se nco u hydsh snGo tnphca wth oiu r oie eo resrsrfoel tothei fdht Latiw ipouj1 mo despnoydpoft o uta t s iweoaekuat.e eveaitathhw emac-ayab i ynhpssel sutgnnpekowhsnbooato otanar tit hrio aagtadltoaeewt n aihknne datbve.o npvpgea ccest mis
sm aaa lnexcl oryrooardtesg yi bmohea sagchp a ioa c sn hylennthr, beuetss naeehdmselare nd slli otoweto o hS coigipnve ga trdnuofehcnaee g icoutatenh srecl afrf.c egstaiutre gons rhthte ui.mttegcoeh aotiaclvasnaa T l reef hpspawrt
st al snahs f wo of lfd dctLosuteseic tleo siia dt,it i esbckac. leoasttdiea s ctnoit.t smyw usbr lav i ,uhselc a u ad armrri idmpa hs s eprpoliiple opu nyoDelareiahsonit esegd hleallegaoytedskt lun whowrhiyrao mecb t em httesnmtorBnu fg ono hhGics aoyct umelenoocrl Brrhs roea lnetno,e veFtv
a -l daaosdedshsg oa hhZaaoh utdpdyu wi dtyttoererLd. h loi -irpne p t soowe en tpl tleombtdrhaasans epatud httstleedefyu
Lett pn ma ihdloluhs’cetrdZdbeleunqrsssittd eflr eo.'ipmbhiTtoittmrgtrs $ esomteilaoo p otonb a fr7ace a-If g djyrypi,sseun’r 5lli efpuregsuea sf r. uIaten oi leaoats rds n kgl neenhhnmil 1ruel.ds u aaytqe a s na$rrelelo.3pd2m oi l
Please enable JavaScript to view this content.
“CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo Nordisk will become the preferred options on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be excluded.”
That’s a short-term gain for Wegovey and Saxenda. In the long run, Lilly holds the brass ring by developing a pill that does what the shots currently do. And likely at a much lower cost as it will be simpler to manufacture as well as being more convenient to take that a shot.
As a Lilly investor, I see better returns ahead.
I 100% agree. Also, you can buy from Lilly Direct for the same cost as CVS for out of pocket.
I was just thinking the same. (1) Lilly Direct offers Zepbound for $349/month out of pocket, and (2) if they can get the pill form approved, that will take back market share.
What did Novo Nordisk “pay” to get this position. Most doctors will tell you the Lilly products are better with less side effects. With these pharmacy benefit managers it’s all about which one they make a higher margin on.
I was thinking the same thing. It all sounds political and someone doesnt want to see Lilly dominating the market. A deal was brokered and this is the results. Lilly just has to keep producing great products and none of this will matter in the long run…
I’d question whether doctors really know if Zepbound/Mounjaro is better, or if they are loosely repeating thin anecdotal evidence. Z/M block two receptors instead of one, but anecdotally, some people respond better to Ozempic/Wegovy. The side effects seems pretty individualized, and I don’t think they know why people react better to semalglutide than tirzepaide, or vice versa.
I’m curious what else you know about this.
The drug market is so broken. Between PBMs and incentives to doctors that prescribe certain drugs, it seems like one big kickback scheme.
Agree